{"status": "Succeeded", "recognitionResults": [{"page": 1, "clockwiseOrientation": 0.04, "width": 1708, "height": 2287, "unit": "pixel", "lines": [{"boundingBox": [200, 206, 1462, 203, 1463, 238, 201, 241], "text": "emerging HT guidelines, changes in HT indications, and formulary restrictions should", "words": [{"boundingBox": [206, 206, 346, 206, 346, 241, 205, 241], "text": "emerging"}, {"boundingBox": [353, 206, 401, 206, 401, 241, 353, 241], "text": "HT"}, {"boundingBox": [408, 206, 571, 206, 571, 241, 408, 241], "text": "guidelines,"}, {"boundingBox": [578, 206, 703, 206, 703, 241, 578, 241], "text": "changes"}, {"boundingBox": [710, 206, 739, 206, 740, 240, 710, 241], "text": "in"}, {"boundingBox": [746, 206, 791, 206, 792, 240, 747, 240], "text": "HT"}, {"boundingBox": [798, 206, 971, 206, 972, 240, 799, 240], "text": "indications,"}, {"boundingBox": [977, 206, 1034, 205, 1036, 239, 979, 239], "text": "and"}, {"boundingBox": [1041, 205, 1182, 205, 1183, 238, 1042, 239], "text": "formulary"}, {"boundingBox": [1189, 205, 1357, 205, 1359, 237, 1190, 238], "text": "restrictions"}, {"boundingBox": [1363, 205, 1461, 205, 1463, 236, 1365, 237], "text": "should"}]}, {"boundingBox": [199, 243, 583, 242, 584, 278, 200, 280], "text": "continue to be monitored.", "words": [{"boundingBox": [205, 245, 333, 243, 333, 277, 205, 280], "text": "continue"}, {"boundingBox": [340, 243, 371, 243, 370, 276, 340, 276], "text": "to"}, {"boundingBox": [378, 243, 417, 243, 417, 276, 377, 276], "text": "be"}, {"boundingBox": [424, 243, 583, 244, 582, 278, 424, 276], "text": "monitored."}]}, {"boundingBox": [200, 316, 1503, 315, 1504, 354, 201, 355], "text": "The opportunity to command a premium price in EX- US markets may be viable if linked", "words": [{"boundingBox": [208, 319, 265, 320, 266, 353, 209, 352], "text": "The"}, {"boundingBox": [271, 320, 439, 320, 440, 354, 272, 353], "text": "opportunity"}, {"boundingBox": [445, 320, 476, 321, 477, 354, 446, 354], "text": "to"}, {"boundingBox": [482, 321, 632, 321, 634, 355, 483, 354], "text": "command"}, {"boundingBox": [639, 321, 658, 321, 660, 355, 640, 355], "text": "a"}, {"boundingBox": [665, 321, 789, 321, 790, 355, 666, 355], "text": "premium"}, {"boundingBox": [804, 321, 878, 321, 880, 355, 806, 355], "text": "price"}, {"boundingBox": [885, 321, 915, 321, 917, 355, 886, 355], "text": "in"}, {"boundingBox": [922, 321, 974, 320, 976, 355, 923, 355], "text": "EX-"}, {"boundingBox": [980, 320, 1028, 320, 1030, 355, 982, 355], "text": "US"}, {"boundingBox": [1035, 320, 1157, 319, 1158, 355, 1037, 355], "text": "markets"}, {"boundingBox": [1163, 319, 1231, 319, 1232, 355, 1165, 355], "text": "may"}, {"boundingBox": [1237, 319, 1279, 319, 1280, 355, 1239, 355], "text": "be"}, {"boundingBox": [1285, 318, 1372, 318, 1374, 354, 1287, 355], "text": "viable"}, {"boundingBox": [1379, 318, 1398, 317, 1400, 354, 1381, 354], "text": "if"}, {"boundingBox": [1405, 317, 1498, 316, 1500, 354, 1407, 354], "text": "linked"}]}, {"boundingBox": [207, 357, 1470, 358, 1469, 393, 206, 392], "text": "to the Totelle comparative data set. A Latin American pricing study is in the field now", "words": [{"boundingBox": [207, 357, 234, 357, 235, 392, 208, 392], "text": "to"}, {"boundingBox": [241, 357, 294, 357, 295, 392, 242, 392], "text": "the"}, {"boundingBox": [301, 358, 401, 358, 402, 393, 301, 392], "text": "Totelle"}, {"boundingBox": [408, 358, 594, 358, 595, 393, 409, 393], "text": "comparative"}, {"boundingBox": [603, 358, 668, 359, 668, 393, 604, 393], "text": "data"}, {"boundingBox": [674, 359, 739, 359, 739, 393, 675, 393], "text": "set."}, {"boundingBox": [746, 359, 768, 359, 769, 393, 746, 393], "text": "A"}, {"boundingBox": [778, 359, 851, 359, 852, 393, 778, 393], "text": "Latin"}, {"boundingBox": [858, 359, 1000, 359, 1001, 393, 859, 393], "text": "American"}, {"boundingBox": [1007, 359, 1110, 359, 1111, 393, 1008, 393], "text": "pricing"}, {"boundingBox": [1117, 359, 1197, 359, 1198, 393, 1118, 393], "text": "study"}, {"boundingBox": [1204, 359, 1232, 359, 1232, 393, 1205, 393], "text": "is"}, {"boundingBox": [1239, 359, 1268, 359, 1269, 393, 1239, 393], "text": "in"}, {"boundingBox": [1275, 359, 1324, 359, 1324, 393, 1276, 393], "text": "the"}, {"boundingBox": [1330, 359, 1395, 359, 1395, 393, 1331, 393], "text": "field"}, {"boundingBox": [1402, 359, 1461, 359, 1461, 393, 1402, 393], "text": "now"}]}, {"boundingBox": [203, 395, 992, 397, 991, 433, 202, 431], "text": "and will help assess this opportunity for the franchise.", "words": [{"boundingBox": [208, 396, 263, 397, 263, 430, 208, 430], "text": "and"}, {"boundingBox": [269, 397, 318, 397, 318, 431, 269, 431], "text": "will"}, {"boundingBox": [324, 397, 393, 398, 392, 432, 324, 431], "text": "help"}, {"boundingBox": [399, 398, 505, 398, 505, 433, 399, 432], "text": "assess"}, {"boundingBox": [511, 398, 566, 398, 566, 433, 511, 433], "text": "this"}, {"boundingBox": [573, 398, 740, 398, 740, 433, 573, 433], "text": "opportunity"}, {"boundingBox": [747, 398, 789, 398, 788, 433, 747, 433], "text": "for"}, {"boundingBox": [795, 398, 844, 398, 844, 433, 795, 433], "text": "the"}, {"boundingBox": [850, 398, 991, 397, 991, 432, 850, 433], "text": "franchise."}]}, {"boundingBox": [199, 470, 557, 473, 556, 510, 198, 506], "text": "5.5 Market Research", "words": [{"boundingBox": [206, 471, 257, 472, 258, 507, 207, 507], "text": "5.5"}, {"boundingBox": [283, 473, 394, 475, 394, 507, 284, 507], "text": "Market"}, {"boundingBox": [402, 475, 556, 475, 555, 509, 402, 507], "text": "Research"}]}, {"boundingBox": [204, 546, 1470, 547, 1469, 586, 203, 584], "text": "The ET/HT picture has evolved since the initial research was conducted in 2000-2001", "words": [{"boundingBox": [209, 546, 265, 547, 266, 585, 210, 585], "text": "The"}, {"boundingBox": [272, 547, 369, 548, 370, 585, 273, 585], "text": "ET/HT"}, {"boundingBox": [377, 548, 479, 549, 479, 585, 378, 585], "text": "picture"}, {"boundingBox": [486, 550, 545, 550, 545, 585, 487, 585], "text": "has"}, {"boundingBox": [552, 550, 667, 551, 667, 585, 553, 585], "text": "evolved"}, {"boundingBox": [675, 551, 754, 551, 754, 585, 675, 585], "text": "since"}, {"boundingBox": [761, 551, 807, 552, 807, 585, 761, 585], "text": "the"}, {"boundingBox": [815, 552, 894, 552, 894, 585, 815, 585], "text": "initial"}, {"boundingBox": [901, 552, 1034, 552, 1033, 585, 901, 585], "text": "research"}, {"boundingBox": [1041, 552, 1102, 552, 1102, 585, 1041, 585], "text": "was"}, {"boundingBox": [1110, 552, 1265, 551, 1265, 585, 1110, 585], "text": "conducted"}, {"boundingBox": [1273, 551, 1304, 551, 1303, 585, 1272, 585], "text": "in"}, {"boundingBox": [1311, 550, 1469, 549, 1468, 585, 1311, 585], "text": "2000-2001"}]}, {"boundingBox": [210, 586, 1465, 589, 1464, 624, 209, 622], "text": "for Premarin/TMG. An apparent shift has been seen since WHI. Physicians appear to", "words": [{"boundingBox": [210, 587, 247, 587, 246, 622, 210, 622], "text": "for", "confidence": "Low"}, {"boundingBox": [253, 587, 485, 589, 484, 623, 253, 622], "text": "Premarin/TMG."}, {"boundingBox": [492, 589, 535, 589, 534, 623, 491, 623], "text": "An"}, {"boundingBox": [542, 589, 677, 590, 676, 623, 541, 623], "text": "apparent"}, {"boundingBox": [684, 590, 746, 590, 744, 623, 683, 623], "text": "shift"}, {"boundingBox": [752, 590, 807, 590, 806, 624, 751, 623], "text": "has"}, {"boundingBox": [814, 590, 892, 590, 891, 624, 813, 624], "text": "been"}, {"boundingBox": [899, 590, 975, 590, 973, 624, 897, 624], "text": "seen"}, {"boundingBox": [981, 590, 1062, 590, 1060, 624, 980, 624], "text": "since"}, {"boundingBox": [1068, 590, 1144, 590, 1142, 624, 1066, 624], "text": "WHI."}, {"boundingBox": [1151, 590, 1316, 590, 1313, 624, 1149, 624], "text": "Physicians"}, {"boundingBox": [1322, 590, 1428, 590, 1425, 624, 1320, 624], "text": "appear"}, {"boundingBox": [1435, 590, 1464, 590, 1462, 624, 1432, 624], "text": "to"}]}, {"boundingBox": [200, 626, 1453, 626, 1453, 663, 201, 664], "text": "have a greater interest in a new progestin versus a lower dose estrogen option. This", "words": [{"boundingBox": [204, 627, 280, 627, 279, 664, 204, 664], "text": "have"}, {"boundingBox": [287, 627, 307, 628, 306, 664, 287, 664], "text": "a"}, {"boundingBox": [314, 628, 422, 628, 421, 664, 314, 664], "text": "greater"}, {"boundingBox": [429, 628, 539, 628, 539, 664, 428, 664], "text": "interest"}, {"boundingBox": [546, 628, 578, 628, 578, 664, 546, 664], "text": "in"}, {"boundingBox": [585, 628, 603, 628, 602, 664, 585, 664], "text": "a"}, {"boundingBox": [610, 628, 671, 628, 671, 664, 609, 664], "text": "new"}, {"boundingBox": [681, 628, 820, 628, 820, 664, 680, 664], "text": "progestin"}, {"boundingBox": [828, 628, 928, 628, 927, 663, 827, 664], "text": "versus"}, {"boundingBox": [935, 628, 955, 628, 954, 663, 935, 663], "text": "a"}, {"boundingBox": [962, 628, 1050, 628, 1049, 663, 961, 663], "text": "lower"}, {"boundingBox": [1058, 628, 1129, 628, 1128, 663, 1057, 663], "text": "dose"}, {"boundingBox": [1136, 628, 1268, 627, 1267, 663, 1135, 663], "text": "estrogen"}, {"boundingBox": [1275, 627, 1381, 627, 1379, 663, 1274, 663], "text": "option."}, {"boundingBox": [1388, 626, 1452, 626, 1450, 663, 1387, 663], "text": "This"}]}, {"boundingBox": [203, 668, 1469, 667, 1470, 700, 204, 701], "text": "changing market dynamic will need to be monitored during the actual launch phase of", "words": [{"boundingBox": [206, 668, 342, 668, 342, 701, 206, 701], "text": "changing"}, {"boundingBox": [348, 668, 456, 669, 457, 702, 349, 701], "text": "market"}, {"boundingBox": [463, 669, 588, 669, 588, 702, 463, 702], "text": "dynamic"}, {"boundingBox": [594, 669, 644, 669, 644, 702, 595, 702], "text": "will"}, {"boundingBox": [650, 669, 728, 669, 728, 702, 651, 702], "text": "need"}, {"boundingBox": [734, 669, 764, 669, 765, 702, 735, 702], "text": "to"}, {"boundingBox": [771, 669, 809, 669, 810, 702, 771, 702], "text": "be"}, {"boundingBox": [816, 669, 969, 669, 970, 701, 817, 702], "text": "monitored"}, {"boundingBox": [977, 669, 1070, 669, 1071, 701, 978, 701], "text": "during"}, {"boundingBox": [1077, 669, 1126, 669, 1127, 701, 1078, 701], "text": "the"}, {"boundingBox": [1135, 669, 1225, 668, 1226, 700, 1136, 701], "text": "actual"}, {"boundingBox": [1232, 668, 1333, 668, 1334, 700, 1233, 700], "text": "launch"}, {"boundingBox": [1339, 668, 1434, 668, 1436, 699, 1341, 700], "text": "phase"}, {"boundingBox": [1441, 668, 1469, 668, 1470, 699, 1442, 699], "text": "of"}]}, {"boundingBox": [202, 703, 1489, 704, 1488, 740, 201, 739], "text": "Low Dose Prempro to gauge the impact on customer attitudes and the management of", "words": [{"boundingBox": [204, 703, 264, 704, 266, 737, 205, 737], "text": "Low"}, {"boundingBox": [275, 704, 356, 705, 357, 738, 277, 737], "text": "Dose"}, {"boundingBox": [362, 705, 494, 706, 496, 739, 364, 738], "text": "Prempro"}, {"boundingBox": [501, 707, 532, 707, 534, 739, 502, 739], "text": "to"}, {"boundingBox": [538, 707, 632, 708, 634, 740, 540, 739], "text": "gauge"}, {"boundingBox": [639, 708, 688, 708, 690, 740, 641, 740], "text": "the"}, {"boundingBox": [695, 708, 797, 708, 799, 740, 697, 740], "text": "impact"}, {"boundingBox": [804, 708, 842, 708, 844, 740, 806, 740], "text": "on"}, {"boundingBox": [849, 708, 989, 708, 991, 740, 851, 740], "text": "customer"}, {"boundingBox": [996, 708, 1125, 708, 1128, 740, 998, 740], "text": "attitudes"}, {"boundingBox": [1132, 708, 1190, 708, 1192, 739, 1134, 740], "text": "and"}, {"boundingBox": [1197, 708, 1243, 707, 1246, 739, 1199, 739], "text": "the"}, {"boundingBox": [1250, 707, 1449, 705, 1451, 737, 1253, 739], "text": "management"}, {"boundingBox": [1455, 705, 1486, 705, 1489, 737, 1458, 737], "text": "of"}]}, {"boundingBox": [203, 741, 1480, 742, 1479, 779, 202, 778], "text": "the symptoms associated with menopause. At this point, market research supports the", "words": [{"boundingBox": [203, 742, 254, 742, 254, 779, 203, 779], "text": "the"}, {"boundingBox": [262, 742, 416, 743, 416, 778, 261, 779], "text": "symptoms"}, {"boundingBox": [424, 743, 583, 743, 583, 778, 424, 778], "text": "associated"}, {"boundingBox": [591, 743, 651, 743, 651, 779, 590, 778], "text": "with"}, {"boundingBox": [658, 743, 845, 743, 844, 779, 658, 779], "text": "menopause."}, {"boundingBox": [852, 743, 884, 743, 883, 779, 852, 779], "text": "At"}, {"boundingBox": [891, 743, 946, 743, 946, 779, 890, 779], "text": "this"}, {"boundingBox": [954, 743, 1036, 743, 1036, 779, 953, 779], "text": "point,"}, {"boundingBox": [1043, 743, 1147, 743, 1147, 779, 1043, 779], "text": "market"}, {"boundingBox": [1155, 743, 1290, 743, 1290, 779, 1154, 779], "text": "research"}, {"boundingBox": [1297, 743, 1426, 743, 1425, 780, 1297, 779], "text": "supports"}, {"boundingBox": [1433, 743, 1479, 743, 1478, 780, 1432, 780], "text": "the"}]}, {"boundingBox": [203, 779, 1390, 780, 1389, 818, 202, 817], "text": "projection that low dose Prempro will drive stabilization of the business and also", "words": [{"boundingBox": [205, 783, 351, 782, 352, 818, 206, 817], "text": "projection"}, {"boundingBox": [358, 782, 416, 781, 416, 818, 358, 818], "text": "that"}, {"boundingBox": [422, 781, 471, 781, 471, 818, 423, 818], "text": "low"}, {"boundingBox": [487, 781, 558, 780, 558, 819, 487, 818], "text": "dose"}, {"boundingBox": [564, 780, 695, 780, 695, 819, 564, 819], "text": "Prempro"}, {"boundingBox": [702, 780, 755, 780, 755, 819, 702, 819], "text": "will"}, {"boundingBox": [762, 780, 833, 780, 832, 819, 762, 819], "text": "drive"}, {"boundingBox": [839, 780, 1017, 780, 1016, 819, 839, 819], "text": "stabilization"}, {"boundingBox": [1024, 780, 1055, 781, 1054, 818, 1023, 819], "text": "of"}, {"boundingBox": [1061, 781, 1110, 781, 1109, 818, 1061, 818], "text": "the"}, {"boundingBox": [1117, 781, 1254, 782, 1253, 817, 1116, 818], "text": "business"}, {"boundingBox": [1261, 782, 1319, 783, 1317, 817, 1260, 817], "text": "and"}, {"boundingBox": [1325, 783, 1390, 784, 1388, 816, 1324, 817], "text": "also"}]}, {"boundingBox": [207, 821, 1465, 820, 1466, 855, 207, 856], "text": "possible market expansion. Premarin/TMG represents an opportunity to drive market", "words": [{"boundingBox": [207, 821, 329, 821, 330, 857, 208, 857], "text": "possible"}, {"boundingBox": [336, 821, 441, 822, 442, 857, 337, 857], "text": "market"}, {"boundingBox": [448, 822, 610, 822, 611, 857, 449, 857], "text": "expansion."}, {"boundingBox": [618, 822, 837, 823, 838, 857, 619, 857], "text": "Premarin/TMG"}, {"boundingBox": [844, 823, 1007, 822, 1008, 856, 846, 857], "text": "represents"}, {"boundingBox": [1014, 822, 1052, 822, 1053, 856, 1015, 856], "text": "an"}, {"boundingBox": [1059, 822, 1226, 822, 1228, 856, 1060, 856], "text": "opportunity"}, {"boundingBox": [1234, 822, 1267, 822, 1268, 856, 1235, 856], "text": "to"}, {"boundingBox": [1274, 822, 1343, 821, 1345, 855, 1275, 856], "text": "drive"}, {"boundingBox": [1351, 821, 1463, 821, 1464, 855, 1352, 855], "text": "market"}]}, {"boundingBox": [205, 859, 415, 861, 414, 895, 204, 893], "text": "share growth.", "words": [{"boundingBox": [207, 860, 292, 861, 292, 893, 208, 893], "text": "share"}, {"boundingBox": [298, 861, 413, 862, 412, 896, 298, 893], "text": "growth."}]}, {"boundingBox": [203, 932, 1505, 933, 1504, 970, 202, 969], "text": "New Qualitative and Quantitative physician research including both Premarin/TMG and", "words": [{"boundingBox": [205, 934, 269, 934, 269, 968, 205, 967], "text": "New"}, {"boundingBox": [282, 934, 443, 935, 443, 969, 282, 968], "text": "Qualitative"}, {"boundingBox": [449, 935, 509, 936, 509, 969, 449, 969], "text": "and"}, {"boundingBox": [515, 936, 696, 936, 696, 970, 515, 969], "text": "Quantitative"}, {"boundingBox": [709, 936, 850, 936, 850, 970, 709, 970], "text": "physician"}, {"boundingBox": [857, 936, 989, 936, 989, 971, 857, 970], "text": "research"}, {"boundingBox": [995, 936, 1132, 935, 1132, 971, 996, 971], "text": "including"}, {"boundingBox": [1138, 935, 1207, 935, 1207, 970, 1139, 971], "text": "both"}, {"boundingBox": [1213, 935, 1429, 933, 1430, 970, 1214, 970], "text": "Premarin/TMG"}, {"boundingBox": [1442, 933, 1501, 933, 1502, 970, 1443, 970], "text": "and"}]}, {"boundingBox": [199, 973, 1438, 973, 1438, 1007, 200, 1008], "text": "Low Dose Prempro has been conducted since the WHI study results were released.", "words": [{"boundingBox": [204, 975, 262, 975, 262, 1007, 205, 1007], "text": "Low"}, {"boundingBox": [274, 975, 357, 975, 358, 1008, 275, 1007], "text": "Dose"}, {"boundingBox": [363, 976, 493, 976, 493, 1008, 364, 1008], "text": "Prempro"}, {"boundingBox": [499, 976, 556, 976, 557, 1008, 499, 1008], "text": "has"}, {"boundingBox": [562, 976, 639, 976, 639, 1008, 563, 1008], "text": "been"}, {"boundingBox": [647, 976, 804, 976, 804, 1008, 648, 1008], "text": "conducted"}, {"boundingBox": [810, 976, 891, 976, 891, 1008, 810, 1008], "text": "since"}, {"boundingBox": [897, 976, 946, 976, 946, 1008, 897, 1008], "text": "the"}, {"boundingBox": [952, 976, 1022, 976, 1022, 1008, 952, 1008], "text": "WHI"}, {"boundingBox": [1029, 976, 1109, 975, 1109, 1008, 1028, 1008], "text": "study"}, {"boundingBox": [1115, 975, 1217, 975, 1217, 1008, 1115, 1008], "text": "results"}, {"boundingBox": [1224, 975, 1300, 974, 1299, 1008, 1223, 1008], "text": "were"}, {"boundingBox": [1306, 974, 1438, 973, 1437, 1008, 1306, 1008], "text": "released."}]}, {"boundingBox": [205, 1049, 1487, 1049, 1488, 1087, 206, 1088], "text": "Qualitative research gauging (Summer 2002) reaction to Premarin/TMG showed most", "words": [{"boundingBox": [206, 1050, 376, 1050, 377, 1087, 207, 1085], "text": "Qualitative"}, {"boundingBox": [383, 1050, 517, 1051, 517, 1087, 384, 1087], "text": "research"}, {"boundingBox": [524, 1051, 645, 1051, 646, 1088, 524, 1088], "text": "gauging"}, {"boundingBox": [652, 1051, 793, 1051, 793, 1088, 653, 1088], "text": "(Summer"}, {"boundingBox": [799, 1051, 885, 1051, 885, 1088, 800, 1088], "text": "2002)"}, {"boundingBox": [891, 1051, 1013, 1051, 1014, 1088, 892, 1088], "text": "reaction"}, {"boundingBox": [1020, 1051, 1050, 1051, 1051, 1088, 1021, 1088], "text": "to"}, {"boundingBox": [1057, 1051, 1275, 1050, 1276, 1087, 1058, 1088], "text": "Premarin/TMG"}, {"boundingBox": [1287, 1050, 1404, 1050, 1405, 1085, 1287, 1086], "text": "showed"}, {"boundingBox": [1411, 1050, 1487, 1049, 1487, 1084, 1412, 1085], "text": "most"}]}, {"boundingBox": [203, 1088, 1514, 1089, 1513, 1125, 202, 1124], "text": "physicians believe the results from WHI are primarily attributable to the MPA component", "words": [{"boundingBox": [203, 1090, 363, 1090, 364, 1123, 204, 1122], "text": "physicians"}, {"boundingBox": [369, 1090, 479, 1090, 480, 1124, 370, 1123], "text": "believe"}, {"boundingBox": [485, 1090, 534, 1090, 534, 1124, 486, 1124], "text": "the"}, {"boundingBox": [540, 1090, 641, 1090, 642, 1125, 541, 1124], "text": "results"}, {"boundingBox": [647, 1090, 706, 1090, 707, 1125, 648, 1125], "text": "from"}, {"boundingBox": [723, 1090, 793, 1089, 793, 1125, 724, 1125], "text": "WHI"}, {"boundingBox": [799, 1089, 847, 1089, 848, 1125, 800, 1125], "text": "are"}, {"boundingBox": [854, 1089, 984, 1089, 985, 1126, 854, 1125], "text": "primarily"}, {"boundingBox": [990, 1089, 1159, 1089, 1160, 1126, 991, 1126], "text": "attributable"}, {"boundingBox": [1165, 1089, 1197, 1089, 1198, 1126, 1166, 1126], "text": "to"}, {"boundingBox": [1203, 1089, 1251, 1089, 1252, 1126, 1204, 1126], "text": "the"}, {"boundingBox": [1258, 1089, 1331, 1089, 1332, 1126, 1259, 1126], "text": "MPA"}, {"boundingBox": [1342, 1089, 1512, 1089, 1513, 1125, 1343, 1126], "text": "component"}]}, {"boundingBox": [207, 1127, 1463, 1129, 1462, 1165, 206, 1163], "text": "of Prempro or expressed legal concerns. They are looking for alternatives to Prempro", "words": [{"boundingBox": [209, 1128, 234, 1128, 233, 1163, 207, 1163], "text": "of"}, {"boundingBox": [241, 1128, 372, 1128, 371, 1164, 240, 1163], "text": "Prempro"}, {"boundingBox": [379, 1128, 412, 1128, 410, 1164, 378, 1164], "text": "or"}, {"boundingBox": [418, 1128, 573, 1128, 572, 1164, 417, 1164], "text": "expressed"}, {"boundingBox": [580, 1128, 656, 1128, 655, 1165, 579, 1164], "text": "legal"}, {"boundingBox": [663, 1128, 813, 1129, 812, 1165, 662, 1165], "text": "concerns."}, {"boundingBox": [820, 1129, 891, 1129, 890, 1165, 819, 1165], "text": "They"}, {"boundingBox": [898, 1129, 947, 1129, 946, 1165, 897, 1165], "text": "are"}, {"boundingBox": [954, 1129, 1064, 1129, 1063, 1165, 953, 1165], "text": "looking"}, {"boundingBox": [1071, 1129, 1115, 1129, 1114, 1165, 1070, 1165], "text": "for"}, {"boundingBox": [1122, 1129, 1293, 1130, 1292, 1165, 1121, 1165], "text": "alternatives"}, {"boundingBox": [1300, 1130, 1332, 1130, 1331, 1165, 1299, 1165], "text": "to"}, {"boundingBox": [1339, 1130, 1463, 1130, 1463, 1165, 1338, 1165], "text": "Prempro"}]}, {"boundingBox": [203, 1166, 1459, 1167, 1459, 1202, 202, 1201], "text": "and are experimenting with combination therapies including NETA - based products,", "words": [{"boundingBox": [205, 1169, 263, 1169, 264, 1201, 206, 1201], "text": "and"}, {"boundingBox": [269, 1169, 319, 1168, 319, 1201, 270, 1201], "text": "are"}, {"boundingBox": [327, 1168, 540, 1167, 541, 1203, 328, 1201], "text": "experimenting"}, {"boundingBox": [546, 1167, 606, 1167, 607, 1203, 547, 1203], "text": "with"}, {"boundingBox": [615, 1167, 797, 1167, 797, 1203, 615, 1203], "text": "combination"}, {"boundingBox": [803, 1167, 941, 1167, 942, 1203, 804, 1203], "text": "therapies"}, {"boundingBox": [948, 1167, 1084, 1167, 1085, 1203, 948, 1203], "text": "including"}, {"boundingBox": [1090, 1167, 1179, 1168, 1180, 1202, 1091, 1203], "text": "NETA"}, {"boundingBox": [1187, 1168, 1208, 1168, 1209, 1202, 1188, 1202], "text": "-"}, {"boundingBox": [1216, 1168, 1312, 1168, 1313, 1201, 1217, 1202], "text": "based"}, {"boundingBox": [1318, 1168, 1456, 1169, 1457, 1200, 1319, 1201], "text": "products,"}]}, {"boundingBox": [198, 1203, 1293, 1207, 1293, 1242, 197, 1238], "text": "herbal -based remedies and SSRIs; some are continuing to use Prempro.", "words": [{"boundingBox": [203, 1205, 299, 1205, 300, 1238, 204, 1238], "text": "herbal"}, {"boundingBox": [305, 1205, 410, 1206, 411, 1238, 306, 1238], "text": "-based"}, {"boundingBox": [416, 1206, 559, 1206, 560, 1239, 417, 1239], "text": "remedies"}, {"boundingBox": [566, 1206, 623, 1207, 624, 1239, 567, 1239], "text": "and"}, {"boundingBox": [632, 1207, 736, 1207, 737, 1240, 633, 1239], "text": "SSRIs;"}, {"boundingBox": [743, 1207, 826, 1207, 827, 1240, 743, 1240], "text": "some"}, {"boundingBox": [832, 1207, 884, 1207, 884, 1241, 833, 1240], "text": "are"}, {"boundingBox": [890, 1207, 1046, 1207, 1046, 1241, 891, 1241], "text": "continuing"}, {"boundingBox": [1052, 1207, 1082, 1207, 1082, 1241, 1053, 1241], "text": "to"}, {"boundingBox": [1089, 1207, 1146, 1207, 1146, 1242, 1089, 1242], "text": "use"}, {"boundingBox": [1153, 1207, 1291, 1207, 1291, 1242, 1153, 1242], "text": "Prempro."}]}, {"boundingBox": [203, 1275, 1468, 1278, 1467, 1320, 202, 1317], "text": "Most physicians were hesitant to use another Prempro given the WHI results. Among", "words": [{"boundingBox": [203, 1278, 278, 1279, 278, 1316, 203, 1315], "text": "Most"}, {"boundingBox": [285, 1279, 442, 1280, 442, 1317, 285, 1316], "text": "physicians"}, {"boundingBox": [449, 1280, 523, 1280, 524, 1317, 449, 1317], "text": "were"}, {"boundingBox": [531, 1280, 651, 1280, 651, 1318, 531, 1317], "text": "hesitant"}, {"boundingBox": [658, 1280, 689, 1280, 690, 1318, 659, 1318], "text": "to"}, {"boundingBox": [697, 1280, 752, 1280, 753, 1318, 697, 1318], "text": "use"}, {"boundingBox": [759, 1280, 872, 1280, 873, 1319, 760, 1318], "text": "another"}, {"boundingBox": [880, 1280, 1012, 1280, 1013, 1319, 880, 1319], "text": "Prempro"}, {"boundingBox": [1019, 1280, 1099, 1280, 1099, 1320, 1020, 1319], "text": "given"}, {"boundingBox": [1106, 1280, 1156, 1280, 1157, 1320, 1107, 1320], "text": "the"}, {"boundingBox": [1163, 1280, 1231, 1279, 1232, 1320, 1164, 1320], "text": "WHI"}, {"boundingBox": [1238, 1279, 1349, 1279, 1350, 1320, 1239, 1320], "text": "results."}, {"boundingBox": [1356, 1279, 1467, 1278, 1468, 1321, 1357, 1320], "text": "Among"}]}, {"boundingBox": [203, 1317, 1497, 1320, 1496, 1357, 202, 1355], "text": "physicians willing to use Prempro low dose, it would be prescribed generally to patients", "words": [{"boundingBox": [203, 1320, 361, 1321, 362, 1355, 204, 1353], "text": "physicians"}, {"boundingBox": [368, 1321, 461, 1321, 462, 1355, 369, 1355], "text": "willing"}, {"boundingBox": [467, 1321, 500, 1321, 501, 1355, 468, 1355], "text": "to"}, {"boundingBox": [506, 1321, 565, 1321, 566, 1356, 507, 1355], "text": "use"}, {"boundingBox": [571, 1321, 699, 1321, 700, 1356, 572, 1356], "text": "Prempro"}, {"boundingBox": [705, 1321, 755, 1321, 756, 1357, 706, 1356], "text": "low"}, {"boundingBox": [770, 1321, 850, 1321, 852, 1357, 771, 1357], "text": "dose,"}, {"boundingBox": [857, 1321, 876, 1321, 877, 1357, 858, 1357], "text": "it"}, {"boundingBox": [883, 1321, 971, 1321, 973, 1357, 884, 1357], "text": "would"}, {"boundingBox": [978, 1321, 1019, 1321, 1020, 1357, 979, 1357], "text": "be"}, {"boundingBox": [1026, 1321, 1186, 1321, 1187, 1358, 1027, 1357], "text": "prescribed"}, {"boundingBox": [1192, 1321, 1331, 1321, 1332, 1358, 1194, 1358], "text": "generally"}, {"boundingBox": [1337, 1321, 1367, 1321, 1369, 1358, 1339, 1358], "text": "to"}, {"boundingBox": [1374, 1321, 1495, 1320, 1497, 1358, 1375, 1358], "text": "patients"}]}, {"boundingBox": [200, 1356, 772, 1359, 771, 1398, 199, 1395], "text": "tapering off existing Prempro therapy.", "words": [{"boundingBox": [205, 1359, 329, 1358, 328, 1396, 204, 1396], "text": "tapering"}, {"boundingBox": [337, 1358, 376, 1358, 375, 1396, 336, 1396], "text": "off"}, {"boundingBox": [383, 1358, 497, 1358, 496, 1396, 382, 1396], "text": "existing"}, {"boundingBox": [505, 1358, 634, 1360, 632, 1396, 503, 1396], "text": "Prempro"}, {"boundingBox": [641, 1360, 773, 1363, 771, 1397, 639, 1397], "text": "therapy."}]}, {"boundingBox": [202, 1435, 1350, 1435, 1351, 1471, 202, 1471], "text": "Premarin/TMG was seen as an alternative to MPA-based Prempro. However,", "words": [{"boundingBox": [204, 1436, 422, 1438, 423, 1471, 205, 1471], "text": "Premarin/TMG"}, {"boundingBox": [431, 1438, 494, 1438, 495, 1471, 432, 1471], "text": "was"}, {"boundingBox": [501, 1438, 577, 1438, 579, 1471, 502, 1471], "text": "seen"}, {"boundingBox": [584, 1438, 622, 1438, 624, 1471, 585, 1471], "text": "as"}, {"boundingBox": [629, 1438, 667, 1438, 669, 1471, 630, 1471], "text": "an"}, {"boundingBox": [674, 1438, 829, 1438, 831, 1471, 675, 1471], "text": "alternative"}, {"boundingBox": [836, 1438, 865, 1438, 867, 1471, 837, 1471], "text": "to"}, {"boundingBox": [872, 1438, 1049, 1437, 1051, 1471, 873, 1471], "text": "MPA-based"}, {"boundingBox": [1056, 1437, 1195, 1436, 1197, 1471, 1058, 1471], "text": "Prempro."}, {"boundingBox": [1202, 1436, 1348, 1435, 1350, 1471, 1204, 1471], "text": "However,"}]}, {"boundingBox": [206, 1473, 1468, 1472, 1468, 1508, 207, 1510], "text": "physicians were unsure of experimenting with a new progestin. Use of Premarin/TMG", "words": [{"boundingBox": [208, 1475, 362, 1476, 361, 1509, 207, 1509], "text": "physicians"}, {"boundingBox": [369, 1476, 442, 1476, 442, 1510, 368, 1509], "text": "were"}, {"boundingBox": [449, 1476, 556, 1476, 556, 1510, 449, 1510], "text": "unsure"}, {"boundingBox": [563, 1476, 594, 1476, 594, 1510, 563, 1510], "text": "of"}, {"boundingBox": [601, 1476, 811, 1476, 811, 1510, 601, 1510], "text": "experimenting"}, {"boundingBox": [817, 1476, 880, 1476, 880, 1510, 817, 1510], "text": "with"}, {"boundingBox": [886, 1476, 907, 1476, 907, 1510, 887, 1510], "text": "a"}, {"boundingBox": [913, 1476, 974, 1476, 974, 1510, 913, 1510], "text": "new"}, {"boundingBox": [985, 1476, 1134, 1475, 1135, 1509, 985, 1510], "text": "progestin."}, {"boundingBox": [1141, 1475, 1204, 1475, 1204, 1509, 1141, 1509], "text": "Use"}, {"boundingBox": [1210, 1474, 1241, 1474, 1242, 1509, 1211, 1509], "text": "of"}, {"boundingBox": [1248, 1474, 1465, 1472, 1465, 1508, 1249, 1509], "text": "Premarin/TMG"}]}, {"boundingBox": [204, 1512, 1490, 1511, 1491, 1549, 205, 1550], "text": "could be limited to patient either requesting \"natural product\", those who failed on other", "words": [{"boundingBox": [205, 1512, 285, 1512, 285, 1549, 205, 1549], "text": "could"}, {"boundingBox": [293, 1512, 331, 1513, 331, 1549, 292, 1549], "text": "be"}, {"boundingBox": [339, 1513, 438, 1513, 437, 1550, 338, 1549], "text": "limited"}, {"boundingBox": [445, 1513, 474, 1513, 473, 1550, 444, 1550], "text": "to"}, {"boundingBox": [481, 1513, 585, 1514, 584, 1550, 480, 1550], "text": "patient"}, {"boundingBox": [593, 1514, 677, 1514, 676, 1550, 592, 1550], "text": "either"}, {"boundingBox": [684, 1514, 842, 1514, 841, 1550, 684, 1550], "text": "requesting"}, {"boundingBox": [849, 1514, 965, 1514, 964, 1550, 848, 1550], "text": "\"natural"}, {"boundingBox": [972, 1514, 1105, 1514, 1104, 1550, 971, 1550], "text": "product\",", "confidence": "Low"}, {"boundingBox": [1113, 1514, 1197, 1514, 1196, 1549, 1112, 1550], "text": "those"}, {"boundingBox": [1205, 1514, 1268, 1513, 1267, 1549, 1204, 1549], "text": "who"}, {"boundingBox": [1275, 1513, 1359, 1513, 1358, 1549, 1274, 1549], "text": "failed"}, {"boundingBox": [1367, 1513, 1405, 1513, 1404, 1548, 1366, 1549], "text": "on"}, {"boundingBox": [1413, 1513, 1490, 1512, 1489, 1548, 1412, 1548], "text": "other"}]}, {"boundingBox": [202, 1551, 919, 1552, 918, 1586, 201, 1585], "text": "therapies, or those seeking innovative therapies.", "words": [{"boundingBox": [205, 1552, 354, 1552, 354, 1586, 204, 1585], "text": "therapies,"}, {"boundingBox": [361, 1552, 392, 1552, 392, 1586, 361, 1586], "text": "or"}, {"boundingBox": [399, 1552, 484, 1552, 485, 1586, 399, 1586], "text": "those"}, {"boundingBox": [491, 1552, 605, 1552, 606, 1586, 491, 1586], "text": "seeking"}, {"boundingBox": [612, 1552, 766, 1553, 768, 1587, 613, 1586], "text": "innovative"}, {"boundingBox": [773, 1553, 916, 1554, 918, 1587, 774, 1587], "text": "therapies."}]}, {"boundingBox": [201, 1626, 1511, 1627, 1511, 1663, 200, 1662], "text": "Quantitative research was conducted in October 2002 to ascertain the key attributes of", "words": [{"boundingBox": [206, 1627, 399, 1627, 398, 1663, 206, 1663], "text": "Quantitative"}, {"boundingBox": [406, 1627, 539, 1627, 539, 1663, 406, 1663], "text": "research"}, {"boundingBox": [546, 1627, 608, 1627, 608, 1663, 546, 1663], "text": "was"}, {"boundingBox": [615, 1627, 770, 1627, 770, 1663, 615, 1663], "text": "conducted"}, {"boundingBox": [777, 1627, 806, 1627, 806, 1664, 777, 1663], "text": "in"}, {"boundingBox": [813, 1627, 934, 1627, 934, 1664, 813, 1664], "text": "October"}, {"boundingBox": [941, 1627, 1018, 1627, 1018, 1664, 942, 1664], "text": "2002"}, {"boundingBox": [1025, 1627, 1056, 1627, 1056, 1664, 1025, 1664], "text": "to"}, {"boundingBox": [1063, 1627, 1201, 1627, 1201, 1664, 1063, 1664], "text": "ascertain"}, {"boundingBox": [1208, 1627, 1256, 1627, 1256, 1664, 1208, 1664], "text": "the"}, {"boundingBox": [1263, 1627, 1320, 1627, 1320, 1664, 1263, 1664], "text": "key"}, {"boundingBox": [1327, 1627, 1465, 1627, 1466, 1664, 1327, 1664], "text": "attributes"}, {"boundingBox": [1472, 1627, 1510, 1627, 1511, 1664, 1473, 1664], "text": "of"}]}, {"boundingBox": [207, 1665, 1448, 1667, 1447, 1703, 206, 1700], "text": "Premarin/TMG that influence share of preference for the product versus competitors,", "words": [{"boundingBox": [207, 1665, 422, 1666, 422, 1701, 207, 1700], "text": "Premarin/TMG"}, {"boundingBox": [432, 1666, 490, 1666, 489, 1702, 432, 1701], "text": "that"}, {"boundingBox": [496, 1666, 633, 1667, 633, 1702, 496, 1702], "text": "influence"}, {"boundingBox": [640, 1667, 726, 1668, 726, 1702, 640, 1702], "text": "share"}, {"boundingBox": [733, 1668, 763, 1668, 763, 1702, 733, 1702], "text": "of"}, {"boundingBox": [770, 1668, 929, 1669, 930, 1702, 770, 1702], "text": "preference"}, {"boundingBox": [936, 1669, 978, 1669, 979, 1702, 937, 1702], "text": "for"}, {"boundingBox": [985, 1669, 1033, 1669, 1034, 1702, 986, 1702], "text": "the"}, {"boundingBox": [1040, 1669, 1156, 1670, 1157, 1702, 1041, 1702], "text": "product"}, {"boundingBox": [1163, 1670, 1265, 1670, 1266, 1701, 1164, 1702], "text": "versus"}, {"boundingBox": [1272, 1670, 1445, 1671, 1447, 1701, 1273, 1701], "text": "competitors,"}]}, {"boundingBox": [201, 1704, 766, 1706, 765, 1741, 200, 1738], "text": "including Prempro low dose products.", "words": [{"boundingBox": [203, 1704, 339, 1706, 340, 1740, 203, 1739], "text": "including"}, {"boundingBox": [346, 1706, 473, 1707, 475, 1740, 347, 1740], "text": "Prempro"}, {"boundingBox": [480, 1707, 530, 1707, 532, 1740, 481, 1740], "text": "low"}, {"boundingBox": [546, 1708, 616, 1708, 618, 1740, 547, 1740], "text": "dose"}, {"boundingBox": [623, 1708, 761, 1707, 764, 1740, 625, 1740], "text": "products."}]}, {"boundingBox": [204, 1781, 1432, 1782, 1431, 1818, 203, 1817], "text": "Physicians expressed an interest in the new products with PCPs expressing more", "words": [{"boundingBox": [204, 1782, 368, 1782, 368, 1818, 204, 1818], "text": "Physicians"}, {"boundingBox": [375, 1782, 532, 1782, 532, 1818, 375, 1818], "text": "expressed"}, {"boundingBox": [539, 1782, 576, 1782, 577, 1818, 539, 1818], "text": "an"}, {"boundingBox": [583, 1782, 693, 1782, 694, 1818, 584, 1818], "text": "interest"}, {"boundingBox": [700, 1782, 731, 1782, 731, 1818, 701, 1818], "text": "in"}, {"boundingBox": [738, 1782, 785, 1782, 785, 1818, 738, 1818], "text": "the"}, {"boundingBox": [792, 1782, 853, 1782, 853, 1818, 792, 1818], "text": "new"}, {"boundingBox": [862, 1782, 993, 1782, 994, 1818, 862, 1818], "text": "products"}, {"boundingBox": [1000, 1782, 1061, 1782, 1062, 1819, 1001, 1818], "text": "with"}, {"boundingBox": [1068, 1782, 1157, 1782, 1158, 1819, 1069, 1819], "text": "PCPs"}, {"boundingBox": [1164, 1782, 1328, 1783, 1329, 1819, 1165, 1819], "text": "expressing"}, {"boundingBox": [1335, 1783, 1417, 1783, 1418, 1819, 1336, 1819], "text": "more", "confidence": "Low"}]}, {"boundingBox": [206, 1820, 1484, 1821, 1483, 1856, 206, 1856], "text": "interest in the Prempro Low Dose family and OBGYNS expressing more of an interest", "words": [{"boundingBox": [207, 1822, 314, 1822, 313, 1856, 206, 1856], "text": "interest"}, {"boundingBox": [321, 1822, 350, 1821, 350, 1856, 320, 1856], "text": "in"}, {"boundingBox": [357, 1821, 408, 1821, 407, 1856, 357, 1856], "text": "the"}, {"boundingBox": [414, 1821, 545, 1821, 544, 1857, 414, 1856], "text": "Prempro"}, {"boundingBox": [551, 1821, 611, 1821, 610, 1857, 551, 1857], "text": "Low"}, {"boundingBox": [622, 1821, 702, 1821, 702, 1857, 622, 1857], "text": "Dose"}, {"boundingBox": [709, 1821, 798, 1822, 798, 1857, 709, 1857], "text": "family"}, {"boundingBox": [805, 1822, 864, 1822, 864, 1857, 805, 1857], "text": "and"}, {"boundingBox": [871, 1822, 1015, 1822, 1015, 1857, 871, 1857], "text": "OBGYNS"}, {"boundingBox": [1022, 1822, 1186, 1822, 1186, 1857, 1022, 1857], "text": "expressing"}, {"boundingBox": [1193, 1822, 1273, 1822, 1273, 1857, 1193, 1857], "text": "more"}, {"boundingBox": [1280, 1822, 1310, 1822, 1309, 1857, 1280, 1857], "text": "of"}, {"boundingBox": [1317, 1822, 1355, 1822, 1355, 1857, 1316, 1857], "text": "an"}, {"boundingBox": [1362, 1822, 1483, 1823, 1483, 1857, 1362, 1857], "text": "interest"}]}, {"boundingBox": [200, 1860, 651, 1858, 652, 1894, 200, 1896], "text": "in the Premarin/TMG product.", "words": [{"boundingBox": [202, 1860, 231, 1860, 232, 1896, 203, 1896], "text": "in"}, {"boundingBox": [238, 1860, 287, 1860, 288, 1895, 239, 1896], "text": "the"}, {"boundingBox": [294, 1860, 514, 1860, 514, 1893, 295, 1895], "text": "Premarin/TMG"}, {"boundingBox": [523, 1860, 651, 1861, 651, 1893, 523, 1893], "text": "product."}]}, {"boundingBox": [198, 1936, 1059, 1932, 1060, 1971, 199, 1974], "text": "Reported advantages of the Premarin/TMG product were:", "words": [{"boundingBox": [203, 1940, 343, 1938, 344, 1972, 204, 1970], "text": "Reported"}, {"boundingBox": [351, 1938, 526, 1937, 528, 1973, 352, 1972], "text": "advantages"}, {"boundingBox": [532, 1937, 564, 1937, 565, 1973, 534, 1973], "text": "of"}, {"boundingBox": [570, 1937, 617, 1936, 618, 1973, 571, 1973], "text": "the"}, {"boundingBox": [625, 1936, 840, 1935, 841, 1972, 626, 1973], "text": "Premarin/TMG"}, {"boundingBox": [852, 1935, 967, 1934, 968, 1971, 853, 1972], "text": "product"}, {"boundingBox": [973, 1934, 1058, 1933, 1059, 1969, 974, 1971], "text": "were:"}]}, {"boundingBox": [198, 2069, 406, 2069, 406, 2106, 199, 2107], "text": "Confidential", "words": [{"boundingBox": [206, 2071, 405, 2069, 404, 2107, 208, 2107], "text": "Confidential"}]}, {"boundingBox": [801, 2072, 937, 2073, 936, 2107, 800, 2105], "text": "21 of 42", "words": [{"boundingBox": [805, 2072, 845, 2073, 846, 2107, 805, 2106], "text": "21"}, {"boundingBox": [852, 2073, 892, 2074, 894, 2107, 853, 2107], "text": "of"}, {"boundingBox": [899, 2074, 935, 2074, 937, 2107, 901, 2107], "text": "42"}]}, {"boundingBox": [21, 2198, 492, 2204, 491, 2235, 20, 2229], "text": "Confidential Pursuant to Confidentiality", "words": [{"boundingBox": [22, 2199, 167, 2201, 167, 2231, 21, 2229], "text": "Confidential"}, {"boundingBox": [173, 2201, 283, 2202, 283, 2233, 173, 2231], "text": "Pursuant"}, {"boundingBox": [289, 2202, 314, 2203, 314, 2233, 289, 2233], "text": "to"}, {"boundingBox": [320, 2203, 490, 2205, 491, 2234, 320, 2233], "text": "Confidentiality"}]}, {"boundingBox": [1430, 2208, 1675, 2208, 1674, 2236, 1429, 2235], "text": "KERZC001-000294", "words": [{"boundingBox": [1436, 2208, 1674, 2210, 1674, 2236, 1436, 2236], "text": "KERZC001-000294"}]}, {"boundingBox": [27, 2234, 99, 2235, 98, 2261, 26, 2260], "text": "Order", "words": [{"boundingBox": [27, 2235, 98, 2235, 99, 2260, 27, 2259], "text": "Order"}]}, {"boundingBox": [372, 2244, 1330, 2241, 1331, 2280, 373, 2282], "text": "Source: https://www.industrydocuments.ucsf.edu/docs/yrvw0217", "words": [{"boundingBox": [379, 2247, 494, 2247, 495, 2280, 380, 2279], "text": "Source:"}, {"boundingBox": [501, 2247, 1329, 2242, 1330, 2279, 501, 2280], "text": "https://www.industrydocuments.ucsf.edu/docs/yrvw0217"}]}]}]}